drugset / Trial / NCT05130515
Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
Phase 2
Completed
6 enrolled
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collabZai Lab (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
According to the definition of National Comprehensive Cancer Network (NCCN), ovarian clear cell carcinoma (OCCC) is a less common subtype of epithelial ovarian cancer (EOC) . The preliminary trial ANNIE (NCT04376073) shows a promising efficacy and safety profile for the ANNIE combo (anlotinib+niraparib). There is limited progress in targeted therapy for those less common ovarian cancers. In this study (CC-ANNIE), we aim to evaluate the antitumor activity and safety of niraparib combined with anlotinib in patients with platinum-resistant or platinum-refractory OCCC.
Timeline
- Start
- 2021-12-15
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Niraparib | Small molecule | 200 mg | Oral |